CTOs on the Move

Valley Research

www.e-vr.com

 
Valley Research is a South Bend, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.e-vr.com
  • 3502 N Olive Rd
    South Bend, IN USA 46628
  • Phone: 574.232.5000

Executives

Name Title Contact Details

Similar Companies

Alicare Medical Management

Alicare Medical Management is a West Harrison, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CoreLink Administrative Solutions

CoreLink Administrative Solutions was launched on January 1, 2009, as a new concept in health care benefits technology. We provide the technology that allows multiple companies to share common core systems and services, resulting in significant cost savings, gains in efficiency and improved capabilities to provide enhanced services. CoreLink is a long-term IT investment funded by Blue Cross Blue Shield of Nebraska and Blue Cross Blue Shield of North Dakota. Working together, the technology experts have built an infrastructure capitalizing on the strengths and experience of both Plans. This investment provides the means to efficiently address the ongoing changes in the health care environment and challenges posed by regulatory requirements, which can add significant costs to Plan operations.

The Scienomics Group

The Scienomics Group is a Greenwich, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharma-Med

Pharma-Med Inc. is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Assembly Biosciences

Assembly Biosciences, Inc. is a biopharmaceutical company developing novel therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly`s proprietary Core Protein Allosteric Modulators (CpAMs) are small molecule, oral agents for the treatment of viral infections. The company`s lead program focuses on hepatitis B (HBV), which infects an estimated 350 million people worldwide and is associated with 600,000 deaths annually. CpAMs alter the HBV core protein, a unique target that is essential to the functioning of the virus. Unlike current therapies that only suppress HBV, CpAMs may have curative potential. Assembly also is developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections.